 | • レポートコード：MRC2303M121 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料によると、世界の骨粗鬆症治療薬市場規模が、予測期間中（2022年〜2027年）に年平均成長率3.4%で拡大すると予測されています。本書は、骨粗鬆症治療薬の世界市場にフォーカスし、最新動向と今後の市場性などをまとめており、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療薬別（副甲状腺ホルモン治療薬、ビスフォスフォネート、カルシトニン、RANKL阻害剤、その他）分析、用途別（原発性骨粗鬆症、続発性骨粗鬆症）分析、地域別（アメリカ 、カナダ 、メキシコ 、ドイツ 、イギリス 、フランス 、イタリア 、スペイン 、中国 、日本、インド 、オーストラリア 、韓国 、中東 、南アフリカ 、ブラジル 、アルゼンチン）分析、競争状況、市場機会・将来の動向などが掲載されています。また、Pfizer Inc.、Eli Lily and Company、F. Hoffmann La Roche、Merck & Co. Inc.、Amgen Inc.、Radius Health Inc.、Teva Pharmaceutical Industries Ltd、GlaxoSmithKline PLC、Novartis International AG、Actavis PLCなど、主要企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の骨粗鬆症治療薬市場規模：治療薬別 - 副甲状腺ホルモン治療薬の市場規模 - ビスフォスフォネートの市場規模 - カルシトニンの市場規模 - RANKL阻害剤の市場規模 - その他の市場規模 ・世界の骨粗鬆症治療薬市場規模：用途別 - 原発性骨粗鬆症における市場規模 - 続発性骨粗鬆症における市場規模 ・世界の骨粗鬆症治療薬市場規模：地域別 - 北米の骨粗鬆症治療薬市場規模 アメリカの骨粗鬆症治療薬市場規模 カナダの骨粗鬆症治療薬市場規模 メキシコの骨粗鬆症治療薬市場規模 … - ヨーロッパの骨粗鬆症治療薬市場規模 イギリスの骨粗鬆症治療薬市場規模 フランスの骨粗鬆症治療薬市場規模 ドイツの骨粗鬆症治療薬市場規模 … - アジア太平洋の骨粗鬆症治療薬市場規模 中国の骨粗鬆症治療薬市場規模 インドの骨粗鬆症治療薬市場規模 日本の骨粗鬆症治療薬市場規模 … - 南米/中東の骨粗鬆症治療薬市場規模 ブラジルの骨粗鬆症治療薬市場規模 アルゼンチンの骨粗鬆症治療薬市場規模 南アフリカの骨粗鬆症治療薬市場規模 … - その他地域の骨粗鬆症治療薬市場規模 ・競争状況 ・市場機会・将来の動向 |
The osteoporosis drugs market is expected to record a CAGR of 3.4% during the forecast period (2022-2027).
Many therapies are being followed worldwide to find reliable COVID-19 treatments. Numerous studies have suggested that in addition to drugs used to treat infections, other drugs such as the drug osteoporosis may be helpful in the treatment of COVID-19, which may boost the market. For example, according to a study published in November 2020, “General treatment of osteoporosis may help reduce the incidence of COVID-19”, treatments such as denosumab, zoledronate, and calcium, are used to treat osteoporosis and COVID-19. The study was conducted by the Pompeu Fabra University, Hospital del Mar Medical Research Institute (IMIM), and Pere Virgili Health Park. According to research, treatment with osteoporosis can reduce COVID-19 infection by 30-40%.
A major factor in the market’s growth is an increase in the incidence of osteoporosis. According to the study titled “Spread and experience of diagnosing osteoporosis in postmenopausal women over the age of 50: Focus on social issues”, published in March 2021, the prevalence of osteoporosis was 34.8%, with a diagnosis rate of 22.1% in South Korea, the highest. The increase in the number of young people worldwide prone to bone growth is another important factor in the market’s growth. For example, according to the International Osteoporosis Foundation, in 2020, 1 in 5 men and 1 in 3 women over the age of 50 may experience osteoporosis fractures in their remaining life.
In addition, the growing investment in R&D by biotechnology and pharmaceutical companies is enhancing the market’s growth. For example, in October 2020, the Italian pharmaceutical authority approved the testing of human clinics with raloxifene. It is a standard orthopedic drug that may help reduce the symptoms of COVID-19. Therefore, positive results from clinical trials can lead to new treatment options, thus boosting the market’s growth. However, strict government regulations are hindering the growth of the market studied.
Osteoporosis Drugs Market Trends
The RANK Ligand Inhibitors Segment is Expected to Dominate the Market Over the Forecast Period
Rank ligand (RANKL) inhibitors are used to treat osteoporosis in patients at high risk of fracture. The high growth potential results from the positive patient outcomes associated with rank ligand inhibitors. Positive patient outcomes can be attributed to significant improvements in bone metabolism. Rank ligand inhibitors can also be used in combination with other drugs to convey the synergistic effect on the entire treatment system. The above-mentioned factor is also expected to be one of the key factors in generating profit. Other benefits associated with rank ligand inhibitors are a reduction in cellular bone density and an increase in bone mineral density, thus increasing their demand.
The Rank ligand may prevent COVID-19. According to a study conducted by a Spanish hospital, Del Mar Hospital, by 2020, denosumab aimed for the RANK/RANKL system, which maintains balance in the skeletal system. It activates the lymph node T-cell and affects the immune system. Inhibition of this system reduces cytokines that cause inflammation in the body and helps control inflammation, which is one of the major risk factors for COVID-19. Thus, due to the widespread use of RANKL, the segment is likely to grow rapidly.
North America Dominates the Market, and May Continue a Similar Trend During the Forecast Period
North America is expected to dominate the overall osteoporosis drugs market throughout the forecast period. The market growth is due to the presence of key players, the high prevalence of osteoporosis patients in the region, established healthcare infrastructure, and the availability of branded drugs.
The United States has the largest market share due to the increasing adult population, a growing number of patients in the country, and several collaborative efforts initiated by large companies to improve their capabilities and ensure higher medical standards. For example, according to the National Osteoporosis Foundation (NOF), since 2020, more than 10 million people in the United States have been diagnosed with osteoporosis, which is more common in menopause. Therefore, the increasing incidence due to menopause in women is expected to be a significant growth factor contributing to the regional drug market for osteoporosis.
COVID-19 disrupts and delays the treatment of many patients with osteoporosis. Hence, the American Society for Bone and Mineral Research (ASBMR) set up an orthopedic committee to oversee the treatment of targeted diseases during the pandemic. For example, in April 2020, a paper on the evidence behind the recommendations was published in the official journal of the American Society for Bone and Mineral Research (ASBMR), Journal of Bone and Mineral Research. The guidelines recommend that patients should continue with osteoporosis medication safely. The introduction of new oral bisphosphonate treatment can be done remotely and should not be delayed in patients at high risk of fracture. Therefore, COVID-19 is expected to significantly impact the market’s growth in North America.
The growing demand is also due to collaborative research programs implemented by major health organizations and companies and the development of new products that constantly strive to improve alternative therapies in the current market environment. For example, in 2019, Amgen announced that the US FDA approved its Evenity (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk of fracture. This factor may open new opportunities for the market’s growth in the region.
Osteoporosis Drugs Market Competitor Analysis
The osteoporosis drugs market is moderately competitive and consists of several major players. Some of the companies currently dominating the market are Pfizer Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc., Amgen Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd, GlaxoSmithKline PLC, Novartis International AG, and Actavis PLC. This industry is anticipated to witness intense competition during the forecast period due to the rising incorporation of collaborative strategies among the key players to sustain the competitive position. The other strategies incorporated are high R&D investments, mergers and acquisitions, and agreements for drug development.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidences of Osteoporosis
4.2.2 Rise in the Geriatric Populations
4.3 Market Restraints
4.3.1 Stringent Regulatory Environment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Drug Type
5.1.1 Parathyroid Hormone Therapy
5.1.2 Bisphosphonates
5.1.3 Calcitonin
5.1.4 RANKL Inhibitors
5.1.5 Other Drug Types
5.2 By Application
5.2.1 Primary Osteoporosis
5.2.2 Secondary Osteoporosis
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Eli Lily and Company
6.1.3 F. Hoffmann La Roche
6.1.4 Merck & Co. Inc.
6.1.5 Amgen Inc.
6.1.6 Radius Health Inc.
6.1.7 Teva Pharmaceutical Industries Ltd
6.1.8 GlaxoSmithKline PLC
6.1.9 Novartis International AG
6.1.10 Actavis PLC
7 MARKET OPPORTUNITIES AND FUTURE TRENDS